MK-571 sodium is a selective, orally active CysLT1 receptor antagonist, which blocks the binding of LTD4, but not LTC4, to human and guinea pig lung membranes with Ki values of 0.22 nM and 2.1 nM, respectively.

MK-571 Sodium is a competitive, potent and selective LTD4 antagonist with Ki values of 0.22 nM.

Cromoglicic acid is used to treat the symptoms of asthma.

LY255283 is selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 μM at human recombinant BLT2 and BLT1 receptors respectively), and inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration.

LY293111 is a potent LTB4 receptor antagonist with IC50 values of 17.6nM and 6.3nM for inhibition of the specific binding of radiolabeled-LTB4 to isolated human neutrophils and the LTB4-induced chemotaxis of human neutrophils, respectively.

Zafirlukast is the first-approved LTR antagonist with anti-asthmatic and potential capsular contracture-preventing activities.

Pranlukast is a selective CysLt1 leukotriene receptor antagonist.

Montelukast Sodium is a potent, selective and competitive LTR1 antagonist with IC50 value < 5 nM, possesssing anti-inflammatory and bronchodilating activities.